There is a growing realisation that the non-cancerous cell types present in the microenvironment of tumours, lymphomas and leukaemias are important auxiliary targets for drug development. 1, 2 In particular, most tumours contain substantial numbers of tumour-associated macrophages (TAMs), and these appear to be polarised towards an M2 macrophage phenotype, which is normally associated with the promotion of angiogenesis and the stimulation of tissue growth.
1,2 M2 macrophages are important for wound healing but in a tumour these same macrophage properties are now thought to promote tumour progression and metastasis. 1, 2 Another property of TAMs is that they may also down modulate the activity of T cells against tumourigenic cells.
3
The FMS receptor for macrophage colony-stimulating factor (M-CSF or CSF-1) is closely related to the KIT and plateletderived growth factor (PDGF) receptors and is important for the production of macrophages, osteoclasts and microglial cells. 4, 5 In addition to tumourigenesis, these cell types are also implicated in various inflammatory, bone and neurological diseases; consequently the FMS receptor is a highly promising therapeutic target. [6] [7] [8] [9] [10] [11] Dasatinib is an adenosine triphosphate (ATP)-based competitor that was developed as a dual inhibitor of the Src family and Abl tyrosine kinases. 12, 13 It is also an effective inhibitor of many of the ephrin receptor family members and of the KIT and PDGF receptors. 12, 14 Dasatinib is reasonably well tolerated by patients and has Food and Drug Administration approval for the treatment of chronic myeloid leukaemia that is resistant to imatinib. 15 Here we report that dasatinib is a potent inhibitor of the FMS receptor and inhibits the production of normal and TAMs and osteoclasts in vitro (IC 50 o1 nM), indicating its potential for the treatment of diseases that are mediated by macrophages or osteoclasts.
An interleukin (IL)-3 dependent cell line FDC-P1 that expresses human recombinant FMS was initially used to test the effect of dasatinib upon FMS signalling, these cells can be stimulated to grow with either M-CSF or IL-3. 10 Dasatinib inhibited the stimulation of growth of FDC-P1fms cells by M-CSF with an IC 50 value of 0.5 nM, as calculated from Figure 1a . As expected, IL-3 stimulated growth of FDC-P1fms cells was unaffected by dasatinib ( Figure 1a) . The oncogenic FMS receptor (FMS D802V) has an equivalent mutation to the frequent leukaemic mutations D816V of KIT and D835V of FLT-3.
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FMSD802V cells were inhibited by dasatinib (Figure 1a ), which agrees with previous reports concerning KITD816V. 17 Figure 1b shows that Rat-2 fibroblasts that express the oncogene v-fms have a transformed morphology, 10 which was suppressed by 1 nM dasatinib (Figure 1c) . Consequently, dasatinib has a potent inhibitory effect upon FMS signalling in fibroblast as well as haematopoietic cell lines.
Figures 1d and e show that 1 nM dasatinib largely inhibited the in vitro kinase activity of FMS and FMS D802VY708F receptors, so establishing that dasatinib is a potent inhibitor of normal and oncogenic FMS. The FMS D802VY708F receptor was analysed because it is a more stable form of the FMS D802V receptor and so is more suitable for biochemistry assays. 10 Dasatinib did not inhibit the in vitro kinase activity of the mutant FMS T663I receptor (Figures 1d and e) , which is in accordance with previous reports that the equivalent mutation of BCR-ABL (T315I) confers resistance to dasatinib. We next assessed the effect of dasatinib upon macrophage and osteoclast production from ovarian tumour ascites samples. The ascites provides a readily available source of cells that is in intimate contact with ovarian tumours and contains both tumour cells and macrophages, which are also referred to as TAMs as they share the characteristic features of M2 macrophages present in tumours. 18 Ascites samples typically contain a population of lymphocytes and a larger population of granular cells. Usually over 80% of granular cells from ovarian tumour ascites samples are CD14 positive (Supplementary Figure S1 C,D) 18 and represent a population of cells of the monocytic lineage. Dasatinib potently inhibited the production of TAMs from all tested ascites samples (n ¼ 7) with an IC 50 value of less than 1 nM (Figure 1f ). We also tested the effect of dasatinib following macrophage differentiation and found that treatment with 5 nM dasatinib killed the vast majority of mature TAMs within 24 h with an IC 50 value of about 1 nM (Figure 1g ). TAMs were identified by their expression of CD68 (Supplementary Figure S1 E, F) and it was also confirmed that these cells expressed the FMS receptor by western blotting (data not shown). As expected, dasatinib also inhibited the production of colonies of macrophages from normal peripheral blood with complete inhibition at less than 10 nM (data not shown). Inhibition of production and killing of mature TAMs was also achieved by imatinib, which is a FMS inhibitor, 9, 10 with an IC 50 value of about 1 mM (Supplementary Figure S1 G, H) . Table 1 shows that 1 nM dasatinib treatment largely inhibited the production of osteoclasts from both normal peripheral blood and from ovarian tumour ascites samples. As expected, osteoclast production from normal blood was dependent upon exogenous M-CSF and receptor activator of nuclear factor-kB ligand (RANKL). However, we found that osteoclasts developed from ascites samples with no requirement for added M-CSF or RANKL (Table 1) . 19 Furthermore, Table 2 shows that imatinib, which is a FMS inhibitor, 9,10 inhibited the production of normal osteoclasts from peripheral blood samples but the same concentrations did not inhibit the production of tumour-associated osteoclasts. A representative photograph of tumour-associated osteoclasts is shown in Supplementary  Figure S1 I, J.
Figures 1h and I model the binding of dasatinib to the ATP-binding pocket of the FMS kinase domain. 20 In support of this model, the predicted hydrogen bonding between dasatinib and the hinge region of FMS is identical to the known hydrogen bonding observed between dasatinib and the active conformation of the kinase domain of Abl, 21 including the key hydrogen bond with the gatekeeper residue, Thr 663 (Figure 1i) . The kinase activation loop of FMS is modelled in its active position to illustrate that dasatinib can bind to the active FMS structure. We would expect that dasatinib can bind to active FMS because it inhibits FMSD802V (Figures 1a-e) , which has a mutation that most probably forces the kinase into its active state. 16 However, the orientation of dasatinib shown in Figures 1h and i is also compatible with binding to the inactive, autoinhibited conformation of FMS (data not shown).
We found that as little as 1 nM dasatinib substantially inhibited the production and survival of macrophages and osteoclasts that were generated from either peripheral blood or from ascites samples from ovarian cancer patients. FMS is probably the key target of dasatinib in TAMs, because TAMs and FMS are equally sensitive to dasatinib and because macrophage production is dependent upon M-CSF addition (Figure 1f) . 4 In support of this TAMs were also inhibited by imatinib (Supplementary Figure S1G , H), at concentrations that are known to inhibit FMS. 10 Osteoclasts have a causal role in bone metastasis and so the finding that dasatinib potently inhibited osteoclast production in vitro (Table 1) is of potential therapeutic value for the treatment of cancers such as multiple myeloma and breast cancer, where bone metastasis often occurs. 19 The key target for dasatinib in normal osteoclastogenesis is again most probably FMS because osteoclast production is dependent upon M-CSF 4 and is inhibited by dasatinib and imatinib at concentrations that match FMS inhibition. By contrast, the same concentrations of imatinib were unable to inhibit osteoclast production from precursor cells present in all tested (n ¼ 7) ascites samples ( Table 2 ). Osteoclast production from ascites also differed from normal in that it occurred independently of added M-CSF or RANKL (Table 2) . Roato et al. 19 have previously reported that osteoclast production from blood samples of patients with a variety of tumours occurs in the absence of M-CSF and RANKL and is unaffected by inhibitors of RANKL signalling. Tumourassociated osteoclasts would therefore appear to be phenotypically distinct from osteoclasts generated from normal peripheral blood. We do not know why dasatinib inhibits tumour-associated osteoclasts but either Src or ephrin receptor inhibition is a possibility. Another distinctive feature of tumourassociated osteoclastogenesis was its stimulation by 0.1 and 0.5 nM dasatinib (Table 2 ). This is possibly because of inhibition of the competing monocyte/macrophage lineage. However, this effect is unlikely to be of clinical significance because serum concentrations of dasatinib in patients are reported to be much higher than 1 nM. 13 Patients treated with high doses of imatinib show some alterations in bone and mineral metabolism consistent with Letters to the Editor impaired osteoclast function. 22, 23 The sensitivity of macrophages and osteoclasts to dasatinib in vitro, indicates that their activity may also be inhibited to some extent by dasatinib given to patients. Imatinib is also reported to stimulate bone mineralisation by osteoblasts through inhibition of the PDGF receptor 23 and so it is possible that dasatinib has a similar effect. 
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The use of macrophage inhibitors for clinical treatment requires careful consideration because macrophages with an M1 phenotype have antitumourogenic properties. 1 Furthermore, dasatinib has been reported to inhibit the activity of other key players of the immune system, including T cells and dendritic cells, 24, 25 although the levels of dasatinib that were used were quite high (10-100 nM) compared to those used here. Given the likely role of macrophages in tumour progression, 1,2 it would seem important to evaluate the use of drugs such as dasatinib as a possible addition to the treatments available for solid tumours. 13.9 ± 0.2 50.9 ± 7.5 0. 5 10.2 ± 1.7 41.6 ± 3.9 1.0 2.6 ± 1.6 7.9 ± 2.2 10 0 0
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